News
Press Release | December 11, 2024
Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies
News | December 9, 2024
Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting Supporting its Novel Approach to Engineered CAR-T Cell Therapies
Press Release | November 13, 2024
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
News | November 12, 2024
Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology
News | November 11, 2024
Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
News | November 7, 2024
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations November 07, 2024 08:30 ET | Source: Palvella Therapeutics
News | October 24, 2024
Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
News | October 23, 2024
Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies
News | October 14, 2024
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024
News | October 10, 2024
Cyrus Biotechnology Congratulates David Baker, 2024 Nobel Laureate in Chemistry and Cyrus Co-Founder
Press Release | September 17, 2024
āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors
News | September 12, 2024
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
Press Release | September 3, 2024
Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months
Press Release | August 14, 2024
Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results
Press Release | July 24, 2024
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
News | July 22, 2024
Vittoria Biotherapeutics Announces Peer-Reviewed Publication in Science Immunology
Press Release | July 10, 2024
Skyhawk Therapeutics Announces Positive Topline Results of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction
Press Release | July 9, 2024
Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
Press Release | June 27, 2024
« Back Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
1
2